MENRIUM 5-2
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MENRIUM 5-2 (MENRIUM 5-2).
Combination of chlordiazepoxide (benzodiazepine) potentiating GABA-A receptor activity, and clidinium (antimuscarinic) blocking muscarinic acetylcholine receptors.
| Metabolism | Chlordiazepoxide: Hepatic via CYP3A4; active metabolite desmethylchlordiazepoxide. Clidinium: Primarily hepatic; exact enzymes not well characterized. |
| Excretion | Chlordiazepoxide: 90-96% renal as metabolites, <5% unchanged; Clidinium: 70-80% fecal, 10-20% renal as metabolites |
| Half-life | Chlordiazepoxide: 5-30 hours (increases with age, hepatic impairment); Clidinium: 8-12 hours |
| Protein binding | Chlordiazepoxide: 95-98% (albumin); Clidinium: 50% (albumin) |
| Volume of Distribution | Chlordiazepoxide: 0.3-0.5 L/kg; Clidinium: 1-2 L/kg (extensive tissue distribution) |
| Bioavailability | Oral: 100% (chlordiazepoxide); 10-20% (clidinium, due to first-pass metabolism) |
| Onset of Action | Oral chlordiazepoxide: 30-60 minutes; oral clidinium: 1-2 hours |
| Duration of Action | Chlordiazepoxide: 6-24 hours (active metabolites extend effect); Clidinium: 3-6 hours (anticholinergic effects) |
| Molecular Weight | Chlordiazepoxide: 299.8 Da; Amitriptyline: 277.4 Da |
1 tablet orally every 6-8 hours as needed for anxiety, up to 4 tablets per day. Each tablet contains chlordiazepoxide 5 mg and clidinium bromide 2.5 mg.
| Dosage form | TABLET |
| Renal impairment | CrCl 30-60 mL/min: no adjustment unless accumulation occurs; CrCl <30 mL/min: avoid due to increased risk of sedation and anticholinergic effects. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B/C: avoid use or reduce dose by 50-75% due to reduced clearance of chlordiazepoxide. |
| Pediatric use | Not recommended for children <18 years old due to lack of safety and efficacy data. |
| Geriatric use | Initial dose: 1 tablet orally once or twice daily; increase slowly to avoid excessive sedation, confusion, and anticholinergic adverse effects; maximum 4 tablets per day. |
| 1st trimester | Avoid due to risk of congenital malformations, particularly neural tube defects, and cardiac malformations. |
| 2nd trimester | Use only if potential benefit justifies risk; may cause fetal growth restriction and neurodevelopmental effects. |
| 3rd trimester | Avoid in late pregnancy due to risk of neonatal withdrawal syndrome (irritability, hypertonia, feeding difficulties) and respiratory depression. |
Clinical note
Comprehensive clinical and safety monograph for MENRIUM 5-2 (MENRIUM 5-2).
| Placental transfer | Both components cross the placenta; chlordiazepoxide and its active metabolite desmethylchlordiazepoxide achieve fetal plasma concentrations similar to maternal; amitriptyline crosses with fetal:maternal ratio of ~1:1. |
| Breastfeeding | Chlordiazepoxide and amitriptyline are excreted into breast milk. Monitor infant for drowsiness, poor feeding, and weight gain. Consider risk of accumulation; use lowest effective dose for shortest duration. |
■ FDA Black Box Warning
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
| Serious Effects |
Concurrent use with MAOIs (risk of serotonin syndrome)Myocardial infarction (acute recovery phase)Severe hepatic impairmentAngle-closure glaucoma (anticholinergic effect of amitriptyline)Urinary retentionHypersensitivity to benzodiazepines or tricyclic antidepressantsBreastfeeding (caution; not absolute but often avoided)
| Precautions | Risk of addiction, abuse, and misuse, Dependence and withdrawal reactions, Concomitant use with opioids, CNS depressant effects and impaired cognition, Paradoxical reactions, Anticholinergic effects (e.g., constipation, urinary retention), Glaucoma risk, Use in elderly or debilitated patients |
| Food/Dietary | Avoid grapefruit juice as it may increase chlordiazepoxide levels. Limit caffeine as it may counteract therapeutic effects. Alcohol is contraindicated due to additive CNS depression. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | FDA Pregnancy Category D. First trimester: increased risk of congenital malformations, particularly cleft palate and cardiovascular defects; second and third trimesters: risk of fetal CNS depression, neonatal withdrawal syndrome, and floppy infant syndrome. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and respiratory status; fetal heart rate monitoring during third trimester; neonatal assessment for withdrawal symptoms and floppy infant syndrome. |
| Fertility Effects | May cause menstrual irregularities, anovulation, and galactorrhea due to hyperprolactinemia; reversible upon discontinuation. |
| Clinical Pearls | Menrium 5-2 (chlordiazepoxide 5 mg + clidinium bromide 2.5 mg) combines a benzodiazepine anxiolytic with an anticholinergic antispasmodic. Use cautiously in elderly due to increased risk of sedation, falls, and anticholinergic effects (constipation, urinary retention, blurred vision). Avoid in narrow-angle glaucoma and myasthenia gravis. Monitor for dependence with prolonged use. Onset of anxiolytic effect occurs within 30-60 minutes; antispasmodic effect peaks at 1 hour. |
| Patient Advice | Take this medication exactly as prescribed; do not increase dose or frequency without consulting your doctor. · Avoid alcohol and other CNS depressants (e.g., opioids, sedatives) as they may increase drowsiness and dizziness. · Do not drive or operate heavy machinery until you know how this medication affects you. · This drug can cause dependence; do not stop abruptly as withdrawal symptoms (anxiety, insomnia, seizures) may occur. · Report persistent dry mouth, constipation, difficulty urinating, or blurred vision to your healthcare provider. · Use caution in hot weather as anticholinergic effects may reduce sweating and increase risk of heat stroke. · Store at room temperature away from moisture and light. |